The Emergence of Bispecific Antibodies to Treat Cancer

Includes a Live Event on 12/16/2021 at 12:00 PM (EST)

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.  

If You DO NOT Have an ACCC Account:  

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.  
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.   
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.   
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.  
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course!

If You Have an ACCC Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.  
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course!  

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!   

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact 

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors.  Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities. 


Murali Janakiram, MBBS, MS 

Assistant Professor, Division of Melanoma 

City of Hope Medical Center 

Amy L. Morris, PharmD 

Clinical Pharmacists, Hematology/Oncology 

University of Virginia Health System 

Nikki Yuill, LCSW (MODERATOR) 

Director, Information Resource Center 

The Leukemia & Lymphoma Society

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register. Please click the "Registration Instructions" tab for more details.

This webinar is part of the Preparing Community Providers for Bispecific Antibodies education project. Funding & support provided by Amgen. 

Murali Janakiram, MBBS, MS

Assistant Professor, Division of Myeloma

City of Hope Medical Center

Murali Janakiram, MD, MS, is a board-certified hematologist/oncologist whose clinical expertise is in multiple myeloma and aggressive lymphomas (e.g., T-cell lymphoma, adult T-cell leukemia/lymphoma, viral associated lymphomas, B-cell lymphomas, and transformed lymphoma). Dr. Janakiram focuses on delivering the best clinical care to the patient, which includes new FDA-approved drugs, access to clinical trial drugs, cellular therapy, and bone marrow transplant.

Every patient is different, and Dr. Janakiram helps patients with lymphoma and myeloma choose the best option. His research interests are in multiple myeloma, T-cell lymphoma, and cellular therapy in lymphoma. In cellular therapy, Dr. Janakiram has extensive experience in taking care and successfully treating patients with CAR T-cell therapy.

Amy L. Morris, PharmD

Clinical Pharmacist, Hematology/Oncology

University of Virginia Health System

Amy Morris, PharmD, is a clinical pharmacist in hematology/oncology at the University of Virginia Health System. Dr. Morris practices as the outpatient clinical pharmacist for malignant hematology, specializing in leukemia and bone marrow failure disorders.

She has published multiple articles on FDA-approved and investigational agents in leukemia, as well as on quality improvement initiatives in oncology practice. Dr. Morris is an active member of the Hematology/Oncology Pharmacy Association (HOPA). She currently serves as a quality improvement coach with the American Society of Clinical Oncology (ASCO) Quality Training Program and helps multidisciplinary teams around the country design and implement quality improvement changes for their cancer care centers.

Nikki Yuill, LCSW (Moderator)

Director, Information Resource Center

The Leukemia & Lymphoma Society

Nikki Yuill is a bilingual (Spanish) Clinical Oncology Social Worker with more than 25 years of healthcare and oncology experience. She attended Purdue University in Indiana for her undergraduate degrees, and she completed her graduate work at the University of Texas at Austin.

Yuill has experience in blood cancers, solid tumors, andhematopoietic stem cell transplantation. She has extensive knowledge of and experience in advocacy, education, and support of blood cancer patients and their families. Yuill has a particular interest in adolescent and young adult cancer care, healthcare disparities, and serving the Latinx community.

Yuill is the director of the Information Resource Center at The Leukemia & Lymphoma Society (LLS), a global leader in the fight against cancer. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Yuill is a proud member of the AOSW (Association of Oncology Social Workers). In 2020 she was awarded the AOSW LLS Oncology-Hematology Lifetime Achievement Award because of her longstanding efforts on behalf of cancer patients.


Pre-Webinar Evaluation
1 Question
The Emergence of Bispecific Antibodies to Treat Cancer
12/16/2021 at 12:00 PM (EST)   |  30 minutes
12/16/2021 at 12:00 PM (EST)   |  30 minutes
Post-Webinar Evaluation
4 Questions